Desperate myeloma patients get early access to promising drug
NCT ID NCT05161598
First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This program provides early access to teclistamab for people with relapsed or refractory multiple myeloma who have run out of standard treatment options. Participants must have tried all available therapies, including proteasome inhibitors, IMiDs, and anti-CD38 antibodies. The goal is to offer a potential treatment option when no others are left.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.